176 related articles for article (PubMed ID: 17024972)
1. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
2. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).
Webber MM; Bello-DeOcampo D; Quader S; Deocampo ND; Metcalfe WS; Sharp RM
Clin Exp Metastasis; 1999 May; 17(3):255-63. PubMed ID: 10432011
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention.
Sharp RM; Bello-DeOcampo D; Quader ST; Webber MM
Mutat Res; 2001 Sep; 496(1-2):163-70. PubMed ID: 11551492
[TBL] [Abstract][Full Text] [Related]
5. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Takahashi N; Sausville EA; Breitman TR
Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of fenretinide on cell-matrix interactions.
Vaccari M; Silingardi P; Argnani A; Horn W; Giungi M; Mascolo MG; Grilli S; Colacci A
Anticancer Res; 2000; 20(5A):3059-66. PubMed ID: 11062723
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
8. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
9. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.
Slawin K; Kadmon D; Park SH; Scardino PT; Anzano M; Sporn MB; Thompson TC
Cancer Res; 1993 Oct; 53(19):4461-5. PubMed ID: 8402613
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.
Tokar EJ; Webber MM
Clin Exp Metastasis; 2005; 22(3):265-73. PubMed ID: 16158254
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Ciolino HP; Wang TT; Sathyamoorthy N
Br J Cancer; 2000 Aug; 83(3):333-7. PubMed ID: 10917548
[TBL] [Abstract][Full Text] [Related]
12. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.
Tokar EJ; Webber MM
Clin Exp Metastasis; 2005; 22(3):275-84. PubMed ID: 16158255
[TBL] [Abstract][Full Text] [Related]
13. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
[TBL] [Abstract][Full Text] [Related]
14. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.
Schwartz GG; Wang MH; Zang M; Singh RK; Siegal GP
Cancer Epidemiol Biomarkers Prev; 1997 Sep; 6(9):727-32. PubMed ID: 9298581
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
16. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide.
Pellegrini R; Mariotti A; Tagliabue E; Bressan R; Bunone G; Coradini D; Della Valle G; Formelli F; Cleris L; Radice P
Cell Growth Differ; 1995 Jul; 6(7):863-9. PubMed ID: 7547508
[TBL] [Abstract][Full Text] [Related]
17. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
19. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.
Quader ST; Bello-DeOcampo D; Williams DE; Kleinman HK; Webber MM
Mutat Res; 2001 Sep; 496(1-2):153-61. PubMed ID: 11551491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
